Why Have Recent Trials of Neuroprotective Agents in Head Injury Failed to Show Convincing Efficacy? A Pragmatic Analysis and Theoretical Considerations
- 1 June 1999
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 44 (6) , 1286-1298
- https://doi.org/10.1227/00006123-199906000-00076
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Factors affecting excitatory amino acid release following severe human head injuryJournal of Neurosurgery, 1998
- Pharmacokinetics of Tirilazad and U-89678, an Active, Reduced Metabolite, following Acute Head Trauma in Adults.Journal of Pharmaceutical Sciences, 1997
- Termination of Acute Stroke Studies Involving Selfotel TreatmentThe Lancet, 1997
- EditorialJournal of Neurotrauma, 1996
- EFFECT OF GENDER AND MENOPAUSAL STATUS ON THE PHARMACOKINETICS OF TIRILAZAD MESYLATE IN HEALTHY SUBJECTSClinical Journal of Sport Medicine, 1995
- A multicenter trial of the efficacy of nimodipine on outcome after severe head injuryJournal of Neurosurgery, 1994
- The Westmead Head Injury Project outcome in severe head injury. A comparative analysis of pre-hospital, clinical and CT variablesBritish Journal Of Neurosurgery, 1993
- A trial of the effect of nimodipine on outcome after head injuryActa Neurochirurgica, 1991
- Ischemic neuronal damage after acute subdural hematoma in the rat: effects of pretreatment with a glutamate antagonistJournal of Neurosurgery, 1991
- Systematic Selection of Prognostic Features in Patients with Severe Head InjuryNeurosurgery, 1980